The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cells' malignancy

Isabella Syring1, Richard Weiten1, Tim Müller2

  • 1Clinic for Urology and Paediatric Urology, University Hospital of Bonn, D-53127 Bonn, Germany.

Oncology Letters
|August 22, 2018
PubMed

Insights

Mediator subunit 15 (MED15) plays a role in urothelial bladder cancer (BCa) progression. While genetic alterations are rare, MED15 influences cell proliferation, migration, and invasion in BCa.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Urothelial Carcinogenesis

Background:

  • The Mediator complex is crucial for gene transcription regulation.
  • Genetic alterations in MED15 have been noted in other cancers, but its role in urothelial bladder cancer (BCa) remains unclear.

Purpose of the Study:

  • To investigate the role of MED15 in urothelial bladder cancer (BCa).
  • To analyze MED15 mRNA expression, protein levels, and its functional impact on BCa cell behavior.

Main Methods:

  • Database analysis of MED15 mRNA expression and survival in BCa using cBioPortal.
  • Immunohistochemistry (IHC) of MED15 on benign, BCa, and metastasis tissue microarrays.
  • Functional studies involving MED15 knockdown via siRNA in BCa cell lines (T24, TCCSUP) to assess proliferation, migration, and invasion.

Main Results:

  • Low frequency (2%) of MED15 genetic alterations observed in BCa mRNA data; no significant survival impact.
  • MED15 protein expression was higher in non-muscle invasive BCa compared to benign and muscle invasive BCa.
  • MED15 knockdown significantly reduced proliferation, migration, and invasion in BCa cell lines.

Conclusions:

  • MED15 expression is altered in BCa, particularly in non-muscle invasive stages.
  • MED15 knockdown demonstrates its functional importance in reducing key BCa tumor parameters.
  • Further research is warranted to fully elucidate MED15's role in BCa pathogenesis and its therapeutic potential.